Company Description
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia.
The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations.
It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations.
Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.
| Country | United States |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 10 |
| CEO | Sumit Aggarwal |
Contact Details
Address: P.O. Box 274 Arlington, Massachusetts 02476 United States | |
| Phone | 781 577 5300 |
| Website | eloxxpharma.com |
Stock Details
| Ticker Symbol | ELOX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001035354 |
| CUSIP Number | 29014R301 |
| ISIN Number | US29014R3012 |
| Employer ID | 84-1368850 |
Key Executives
| Name | Position |
|---|---|
| Sumit Aggarwal M.B.A. | President, Chief Executive Officer and Director |
| Daniel E. Geffken M.B.A. | Interim Chief Financial Officer |
| Barbara A. Ryan | Investor Relations Officer |
| Dr. Ali Hariri M.D. | Chief Medical Officer |